Tau-pathology occurs downstream of Aβ accumulation in Alzheimer’s disease.59–61 The ablation or reduction of endogenous, nonaggregated WT tau prevents or diminishes Aβ toxicity in vitro and in vivo. Here, MAPT is linked to early-onset autosomal dominant Alzheimer disease.